University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.

Deep Genomics, a Canada-based RNA therapy developer based on research at University of Toronto, has raised $180m in a series C round led by telecoms firm SoftBank’s Vision Fund 2. The round also featured Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.